肝癌の診療を極める

出版社: 文光堂
著者:
発行日: 2014-09-21
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784830618949
電子書籍版: 2014-09-21 (第1版第2刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

11,000 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

11,000 円(税込)

商品紹介

新しい造影剤による画像検査,ラジオ波焼灼療法(RFA)など,新しい診療技術の登場だけなく,肝移植の増加,分子標的治療薬の開発の進行など,肝癌診療の進化は着実に進んでいる.本書は,国内のトップクラスの研究者や臨床家の執筆により,肝癌診療を最新の基礎研究と臨床の最先端の両面から深く掘り下げ,肝癌の診療や研究の現在と将来像までを見通せる内容としている.肝癌診療に携わる臨床医には必携の一冊.

目次

  • 肝癌の診療を極める

    ―目次―

    ?.基本編 〜肝癌を診る前の基礎知識〜
     1.原発性肝癌の種類
     2.肝癌の疫学
     3.ウイルス肝炎からの発癌
     4.非ウイルス性肝疾患からの発癌
     5.発癌リスクの推定
     6.発癌抑制

    II.診断編
     A.肝細胞癌編
     B.その他の原発性肝癌

    III.治療編
     A.経皮的治療
     B.経カテーテル治療
     C.化学療法・分子標的薬
     D.肝切除
     E.肝移植
     F.放射線療法・粒子線療法
     G.肝細胞癌の治療選択
     H.再発抑制を目指した治療方針
     I.肝細胞癌以外の肝癌の治療

    IV.肝癌を理解するための基礎研究
     1.SNP,GWAS
     2.whole genome sequence(全ゲノム解読)による肝癌の解析
     3.stem cell
     4.分子標的薬の作用機序
     5.免疫療法

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 基本編~肝癌を診る前の基礎知識~

P.5 掲載の参考文献
1) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
2) Bosman F, Carneiro F, Hruban RH, et al. (eds) : WHO classification of tumours of the digestive system, fourth edition, IARC, 2010
3) 日本肝癌研究会 : 第18回全国原発性肝癌追跡調査報告, 2009
P.13 掲載の参考文献
1) 平成24年 (2012年) 人口動態統計 (確定数) の概況 : 厚生労働省 統計情報・白書 厚生労働省HP : http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/
2) WHO, International Agency for Research on Cancer, GLOBOCAN 2008 http://globocan.iarc.fr/
3) 日本肝癌研究会 : 第5~第18回全国原発性肝癌追跡調査報告, 日本肝癌研究会事務局, 1982-2009.
4) Yoshizawa H, Tanaka J : International Kilmer Conference Proceedings, vol 8. p247-264, 2004より引用, 改変2014
5) 肝がん死亡の地理的分布, 平成21年度厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業「肝炎状況・長期予後の疫学に関する研究」班 報告書 2010
6) Tanaka J, Kumagai J, Katayama K, et al. : Sex-and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3, 485, 648 first-time blood donors during 1995-2000. Intervirology 47 : 32-40, 2004
7) Tanaka J, Koyama T, Mizui M, et al. : Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology 54 : 185-195, 2011
8) Tanaka J, Kumada H, Ikeda K, et al. : Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 70 : 378-386, 2003
9) 肝炎ウイルス持続感染者の病態推移に関する数理疫学的研究, 平成24年度厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業「肝炎ウイルス感染状況・長期経過と予後調査及び治療導入対策に関する研究」班 報告書, 2013
P.17 掲載の参考文献
1) El-Serag HB : Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142 ; 1264-1273 e 1, 2012
2) Arase Y, Kobayashi M, Suzuki F, et al. : Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 ; 964-973, 2013
3) Bouchard MJ, Navas-Martin S. : Hepatitis B and C virus hepatocarcinogenesis : lessons learned and future challenges. Cancer Lett 305 ; 123-143, 2011
4) Yoshida H, Shiratori Y, Moriyama M, et al. : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 ; 174-181, 1999
5) Moriya K, Fujie H, Shintani Y, et al. : The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 ; 1065-1067, 1998
P.21 掲載の参考文献
1) Tokushige K, Hashimoto E, Horie Y, et al. : Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology : report of the nationwide survey. J Gastroenterol 46 ; 1230-1237, 2011
2) Michitaka K, Nishiguchi S, Aoyagi Y, et al. : Etiology of liver cirrhosis in Japan : a nationwide survey. J Gastroenterol 45 ; 86-94, 2010
3) Suzuki Y, Ohtake T, Nishiguchi S, et al. : Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res 43 ; 1020-1031, 2013
5) Tokushige K, Kodama K, Hashimoto E : Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol 28 Suppl 4 ; 88-92, 2013
7) Harada K, Hirohara J, Ueno Y, et al. : Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis : national data from Japan. Hepatology 57 ; 1942-1949, 2013
8) Torisu Y, Ikeda K, Kobayashi M, et al. : Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis : A preliminary report. Hepatol Res 37 ; 517-523, 2007
9) Hashimoto E, Tokushige K : Hepatocellular carcinoma in non-alcoholic steatohepatitis : Growing evidence of an epidemic? Hepatol Res 42 ; 1-14, 2012
P.26 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年度版. 金原出版, 2013
2) Liaw YF, Sung JJ, Chow WC, et al. : Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 ; 1521-1531, 2004
3) Hosaka T, Suzuki F, Kobayashi M, et al. : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 ; 98-107, 2013
4) Wong GL, Wong VW : Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 19 ; 6515-6522, 2013
5) Wong VW, Chan SL, Mo F, et al. : Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28 ; 1660-1665, 2010
6) Yuen MF, Tanaka Y, Fong DY, et al. : Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 50 ; 80-88, 2009
7) Yang HI, Yuen MF, Chan HL, et al. : Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) : development and validation of a predictive score. Lancet Oncol 12 ; 568-574, 2011
8) Wong GL, Chan HL, Chan HY, et al. : Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 144 ; 933-944, 2013
9) Masuzaki R, Tateishi R, Yoshida H, et al. : Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49 ; 1954-1961, 2009
10) Yoshida H, Shiratori Y, Moriyama M, et al. : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 ; 174-181, 1999
12) Calle EE, Rodriguez C, Walker-Thurmond K, et al. : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 ; 1625-1638, 2003
13) Chen CL, Yang HI, Yang WS, et al. : Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection : a follow-up study in Taiwan. Gastroenterology 135 ; 111-121, 2008
14) Tyson GL, El-Serag HB : Risk factors for cholangiocarcinoma. Hepatology 54 ; 173-184, 2011
P.31 掲載の参考文献
1) Ikeda K, Saitoh S, Suzuki Y, et al. : Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus : a pilot study. Cancer 82 ; 827-835, 1998
2) Wong GL, Yiu KK, Wong VW, et al. : Meta-analysis : reduction in hepatic events following interferonalfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 32 ; 1059-1068, 2010
3) Liaw YF, Sung JJ, Chow WC, et al. : Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 ; 1521-1531, 2004
4) Hosaka T, Suzuki F, Kobayashi M, et al. : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 ; 98-107, 2013
5) Yoshida H, Shiratori Y, Moriyama M, et al. : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 ; 174-181, 1999
6) Nishiguchi S, Shiomi S, Nakatani S, et al. : Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357 ; 196-197, 2001
7) Camma C, Giunta M, Andreone P, et al. : Interferon and prevention of hepatocellular carcinoma in viral cirrhosis : an evidence-based approach. J Hepatol 34 ; 593-602, 2001
8) Singal AK, Singh A, Jaganmohan S, et al. : Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8 ; 192-199, 2010
9) Ikeda K, Arase Y, Saitoh S, et al. : Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32 ; 228-232, 2000
10) Lok AS, Everhart JE, Wright EC, et al. : Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140 ; 840-849, 2011
12) Kobayashi M, Ikeda K, Arase Y, et al. : Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 43 ; 63-70, 2008
13) Muto Y, Moriwaki H, Ninomiya M, et al. : Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334 ; 1561-1567, 1996
14) Muto Y, Moriwaki H, Saito A : Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340 ; 1046-1047, 1999
15) Okita K, Izumi N, Matsui O, et al. : Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma : a randomized double-blind placebo-controlled study. J Gastroenterol, in press.
P.33 掲載の参考文献
1) Kumagai S, Kurumatani N, Arimoto A et al. : Cholangiocarcinoma among offset colour proofprinting workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med 70 ; 508-510, 2013
2) Kubo S, Nakanuma Y, Takemura S et al. : Case-series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 21 ; 479-488, 2014
3) 厚生労働省 : 「印刷事業場で発生した胆管がんの業務上外に関する検討会」報告書, 化学物質ばく露と胆管がん発症との因果関係について~大阪の印刷事業場の症例からの検討~. 2013

II. 診断編

P.40 掲載の参考文献
1) Mauri G, Cova L, De Beni S, et al. : Real-Time US-CT/MRI Image Fusion for Guidance of Thermal Ablation of Liver Tumors Undetectable with US : Results in 295 Cases. Cardiovasc Intervent Radiol 2014 May 8. [Epub ahead of print]
2) Cassinotto C, Lapuyade B, Mouries A, et al. : Non-invasive assessment of liver fibrosis with impulse elastography : Comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol pii ; S0168-8278 (14) 00307-9, 2014
3) Honjo M, Moriyasu F, Sugimoto K, et al. : Relationship between the liver tissue shear modulus and histopathologic findings analyzed by intraoperative shear wave elastography and digital microscopically assisted morphometry in patients with hepatocellular carcinoma. J Ultrasound Med 33 ; 61-71, 2014
P.45 掲載の参考文献
1) Murashima S, Tanaka M, Haramaki M, et al. : A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 51 ; 808-812, 2006
2) Tateyama M, Yatsuhashi H, Taura N, et al. : Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 46 ; 92-100, 2011
3) Aoyagi Y, Suzuki Y, Isemura M, et al. : Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann 75 ; 809-815, 1984
4) Aoyagi Y, Isemura M, Yosizawa Z, et al. : Fucosylation of serum alpha-fetoprotein in patient with primary hepatocellular carcinoma. Biochim Biophys Acta 830 ; 217-223, 1985
5) Aoyagi Y, Suzuki Y, Igarashi K, et al. : Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma : Presence of fucosylated and non-fucosylated triantennary glycans. Brit J Cancer 67 ; 486-492, 1993
6) Aoyagi Y, Isemura M, Suzuki Y, et al. : Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 2 ; 1353-1354, 1985
7) Aoyagi Y, Suzuki Y, Isemura M, et al. : The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 61 ; 769-774, 1988
8) Taketa K, Ichikawa E, Taga H, et al. : Antiboby-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 6 ; 492-497, 1985
9) Tamura Y, Igarashi M, Kawai H, et al. : Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 55 ; 3576-3583, 2010
10) Yamashita F, Tanaka M, Satomura S, et al. : Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 111 ; 996-1001, 1996
11) Aoyagi Y, Isokawa O, Suda T. et al. : The fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 83 ; 2076-2082, 1998
12) Tamura Y, Suda T, Arii S, et al. : Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci 58 ; 2406-2412, 2013
13) Liebman HA, Furie BC, Tong MJ, et al. : Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Eng J Med 310 ; 1427-1431, 1984
14) Mita Y, Aoyagi Y, Yanagi M, et al. : Usefulness of sensitive determination of des-gamma-carboxy prothrombin in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 ; 1643-1648, 1998
15) Aoyagi Y, Oguro M, Yanagi M, et al. : Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence of patients with hepatocellular carcinoma. Cancer 77 ; 1781-1786, 1996
P.52 掲載の参考文献
1) Filmus J, Church J G, Buick R N : Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 8 ; 4243-4249, 1988
2) Hsu HC, Cheng W, Lai PL : Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma : biological significance and temporospatial distribution. Cancer Res 57 ; 5179-5184, 1997
3) Zhu Z W, Friess H, Wang L, et al. : Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48 ; 558-564, 2001
4) Capurro M, Wanless I R, Sherman M, et al. : Glypican-3 : a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 ; 89-97, 2003
5) Hippo Y, Watanabe K, Watanabe A, et al. : Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64 ; 2418-2423, 2004
6) Chen M, Li G, Yan J, et al. : Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 423 ; 105-111, 2013
7) Capurro M I, Xiang Y Y, Lobe C, et al. : Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65 ; 6245-6254, 2005
8) Capurro M I, Shi W, Sandal S, et al. : Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem 280 ; 41201-41206, 2005
9) Filmus J, Capurro M : Glypican-3 : a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280 ; 2471-2476, 2013
10) Takashima M, Kuramitsu Y, Yokoyama Y, et al. : Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 3 ; 2487-2493, 2003
11) Chuma M, Sakamoto M, Yamazaki K, et al. : Expression profiling in multistage hepatocarcinogenesis : identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37 ; 198-207, 2003
12) Di Tommaso L, Franchi G, Park YN, et al. : Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 ; 725-734, 2007
13) Kawakami T, Hoshida Y, Kanai F, et al. : Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5 ; 4287-4295, 2005
14) 三善英知, 鎌田佳宏, 魚住尚史 : 糖鎖がんマーカー. 実験医学 31 ; 1526-1532, 2013
15) Block TM, Comunale MA, Lowman M, et al. : Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 102 ; 779-784, 2005
16) Kladney RD, Bulla GA, Guo L, et al. : GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 249 ; 53-65, 2000
17) Kawamoto S, Moriwaki K, Nakagawa T, et al. : Overexpression of alpha1,6-fucosyltransferase in hepatoma enhances expression of Golgi phosphoprotein 2 in a fucosylation-independent manner. Int J Oncol 39 ; 203-208, 2011
18) Liang H, Block TM, Wang M, et al. : Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark 11 ; 161-171, 2012
19) Mao Y, Yang H, Xu H, et al. : Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 59 ; 1687-1693, 2010
20) Riener MO, Stenner F, Liewen H, et al. : Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 49 ; 1602-1609, 2009
21) Yamamoto K, Imamura H, Matsuyama Y, et al. : AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 45 ; 1272-1282, 2010
22) Yamamoto Y, Kosaka N, Tanaka M, et al. : MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14 ; 529-538, 2009
23) Giordano S, Columbano A : MicroRNAs : new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57 ; 840-847, 2013
24) Kojima K, Takata A, Vadnais C, et al. : MicroRNA122 is a key regulator of alpha-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun 2 ; 338, 2011
25) Kamada Y, Fujii H, Sawai Y, et al. : Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl 2013.
26) Kamada Y, Akita M, Takeda Y, et al. : Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS One. 8 : e66328, 2013.
P.58 掲載の参考文献
1) 日本肝癌研究会 (編) : 第18回全国原発性肝癌追跡調査報告 (2004-2005). メディア・プランニング, 2009
2) Ichikawa T, Erturk SM, Araki T : Multiphasic contrast-enhanced multidetector-row CT of liver : contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol 58 ; 165-176, 2006
3) Yamashita Y, Komohara Y, Takahashi M, et al. : Abdominal helical CT : evaluation of optimal doses of intravenous contrast material-a prospective randomized study. Radiology 216 ; 718-723, 2000
4) Yanaga Y, Awai K, Nakaura T, et al. : Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT. AJR Am J Roentgenol 190 ; 1003-1009, 2008
5) Awai K, Hiraishi K, Hori S : Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight. Radiology 230 ; 142-150, 2004
6) 日本腎臓学会, 日本医学放射線学会, 日本循環器学会 : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012. 東京医学社, 2012
7) Takayasu K, Furukawa H, Wakao F, et al. : CT diagnosis of early hepatocellular carcinoma : sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 164 ; 885-890, 1995
8) Katayama H, Yamaguchi K, Kozuka T, et al. : Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 175 ; 621-628, 1990
9) 鳴海善文, 中村仁信 : 非イオン性ヨード造影剤およびガドリニウム造影剤の重症副作用および死亡例の頻度調査. 日本医放会誌 65 ; 300-301, 2005
P.64 掲載の参考文献
1) 角谷眞澄 : 脂肪のすべて : MRIは脂肪が面白い. 消化器画像 7 ; 573-581, 2005
2) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
3) Kadoya M, Matsui O, Takashima T, et al. : Hepatocellular carcinoma : correlation of MR imaging and histopathologic findings. Radiology 183 ; 819-825, 1992
4) Matsui M, Kadoya M, Kameyama T, et al. : Adenomatous hyperplastic nodules in the cirrhotic liver : differentiation from hepatocellular carcinoma with MR imaging. Radiology 173 ; 123-126, 1989
5) Xu PJ, Yan FH, Wang JH, et al. : Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr 34 ; 506-512, 2010
6) 谷本伸弘編 : 肝の最新MRI. 金原出版, 2004
7) 角谷眞澄 ; Paradoxical negative enhancement-肝ダイナミックMRIにおけるピットフォール. 肝胆膵画像 14 ; 555-565, 2012
8) Imai Y, Murakami T, Yoshida S, et al. : Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma : Correlation with histologic grading. Hepatology 32 ; 205-212, 2000
9) Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. : Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183 ; 59-64, 1992
P.70 掲載の参考文献
1) Narita M, Hatano E, Arizono S, et al. : Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44 ; 793-798, 2009
2) Kitao A, Zen Y, Matsui O, et al. : Hepatocellular carcinoma : signal intensity at gadoxetic acid-enhanced MR imaging : correlation with molecular transporters and histopathologic features. Radiology 256 ; 817-826, 2010
3) Tsuboyama T, Onishi H, Kim T, et al. : Hepatocellular carcinoma : hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255 ; 824-833, 2010
4) Kogita S, Imai Y, Okada M, et al. : Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma : correlation with histological grading and portal blood flow. Eur Radiol 20 ; 2405-2413, 2010
5) Sano K, Ichikawa T, Motosugi U, et al. : Imaging study of early hepatocellular carcinoma : usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261 ; 834-844, 2011
6) Kitao A, Matsui O, Yoneda Y, et al. : The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis : correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21 ; 2056-2066, 2011
7) Kitao A, Matsui O, Yoneda N, et al. : Hypervascular hepatocellular carcinoma : correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265 : 780-789, 2012
8) Yoneda N, Matsui O, Kitao A, et al. : Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid enhanced magnetic resonance imaging : a possible subtype with mature hepatocyte nature. Jpn J Radiol 31 : 480-490, 2013
9) Yamashita T, Forgues M, Wang W, et al. : Ep-CAM and a-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 ; 1451-1461, 2008
10) Yamashita T, Kitao A, Matsui O, et al. : Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014 Epub ahead of print.
P.74 掲載の参考文献
1) Kobayashi S, Nakanuma Y, Matsui O : Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases : a histological survey. Hum Pathol 25 ; 940-946, 1994
2) Hayashi M, Matsui O, Ueda K, et al. : Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis : evaluation by CT during intraarterial injection of contrast medium. Am J Roentgenol 172 ; 969-976, 1999
3) Matsui O, Kadoya M, Kameyama T, et al. : Benign and malignant nodules in cirrhotic livers : distinction based on blood supply. Radiology 178 ; 493-497, 1991
4) Ueda K, Matsui O, Kawamori Y, et al. : Hypervascular hepatocellular carcinoma : evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 206 ; 161-166, 1998
5) Miyayama S, Matsui O, Yamashiro M, et al. : Detection of hepatocellular carcinoma by CT during arterial portography using a cone-beam CT technology : comparison with conventional CTAP. Abdom Imaging 34 ; 502-506, 2009
6) Yamagami T, Nakamura T, Sato O, et al. : Value of intraarterial prostaglandin E (1) injection during CT hepatic arteriography. Am J Roentgenol 177 ; 115-119, 2001
7) Hayashi M, Matsui O, Ueda K, et al. : Progression to hypervascular hepatocellular carcinoma : correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225 ; 143-149, 2002
8) Kitao A, Zen Y, Matsui O, et al. : Hepatocarcinogenesis : multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology 252 ; 605-614, 2009
9) Ueda K, Matsui O, Kawamori Y, et al. : Differentiation of hypervascular hepatic pseudolesions from hepatocellular carcinoma : value of single-level dynamic CT during hepatic arteriography. J Comput Assist Tomogr 22 ; 703-708, 1998
P.78 掲載の参考文献
1) Higashi T, Tamaki N, Honda T, et al. : Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 38 ; 1337-1344, 1997
2) Torizuka T, Tamaki N, Inokuma T, et al. : In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36 ; 1811-1817, 1995
3) Seo S, Hatano E, Higashi T, et al. : Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13 (2 Pt 1) ; 427-433, 2007
4) Hatano E, Ikai I, Higashi T, et al. : Preoperative positron emission tomography with fluorine- 18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30 ; 1736-1741, 2006
5) Kornberg A, Kupper B, Tannapfel A, et al. : Patients with non- [18F] fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 18 ; 53-61, 2012
6) Lin CY, Chen JH, Liang JA, et al. : 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma : a systematic review and meta-analysis. Eur J Radiol 81 ; 2417-2422, 2012
7) Witjes CD, Verhoef C, Kwekkeboom DJ, et al. : Is bone scintigraphy indicated in surgical work-up for hepatocellular carcinoma patients? J Surg Res 181 ; 256-261, 2013
8) Higashi T, Hatano E, Ikai I, et al. : FDG PET as a prognostic predictor in the early psot-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 37 ; 468-482, 2010
9) Lee JH, Park JY, Kim do Y, et al. : Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 31 ; 1144-1149, 2011
10) Hayakawa N, Nakamoto Y, Nakatani Y, et al. : Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol 2013 Dec 25. [Epub ahead of print]
P.81 掲載の参考文献
1) 木村達, 大崎征夫, 小東克次, 他 : 超音波誘導下肝生検-4年間917例の検討-. 映像情報Med 26 ; 1473-1475, 1994
2) 高橋祥一, 北本幹也, 相方浩, 他 : 肝腫瘍穿刺の合併症に関する検討. 臨と研 77 ; 1384-1388, 2000
3) 真島康雄, 藤本隆史, 岩井一郎, 他 : 新しいエコー下細径針組織生検法による肝細胞癌の組織診断とその意義. 肝臓 29 ; 628-636, 1988
4) 肝腫瘍生検研究会 : 肝腫瘍生検ならびにエタノール局注療法 (PEIT) の合併症アンケート調査報告. 肝腫瘍生検と画像 第3巻, 国際図書出版, 209-211, 1990
5) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2009年版. 金原出版, p 54-55, 2009
6) Chang S, Kim SH, Lim HK, et al. : Needle tract implantation after percutaneous interventional procedures in hepatocellular carcinomas : lessons learned from a 10-year experience. Korean J Radiol 9 ; 268-274, 2008
7) Wang P, Meng ZQ, Chen Z, et al. : Diagnostic value and complications of fine needle aspiration for primary liver cancer and its influence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol 34 ; 541-546, 2008
8) Colecchia A, Scaioli E, Montrone L, et al. : Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 54 ; 300-305, 2011
9) 日本肝臓学会編 : サーベイランスアルゴリズム・診断アルゴリズムの解説. 科学的根拠に基づく肝癌診療ガイドライン 2013年版, 金原出版, p 13, 2013
10) Manini MA, Sangiovanni A, Fornari F, et al. : Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol 60 ; 995-1001, 2014
P.88 掲載の参考文献
1) 日本肝癌研究会 : 第18回全国原発性肝癌追跡調査報告 (2004-2005). 2009
2) Theise ND, Curado MP, Franceschi S, et al. : Hepatocellular carcinoma. WHO classification of tumors of the digestive system 4 th ed. Lyon : IARC ; pp 205-216, 2010
3) Lee JS, Hero J, Libbrecht L, et al. : A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 ; 410-416, 2006
4) Yoneda N, Sato Y, Kitao A, et al. : Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth ablitities in human hepatocellular carcinoma. Lab Invest 91 ; 262-272, 2011
5) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
6) International Consensus Group for Hepatocellular Neoplasia : Pathologic diagnosis of early hepatocellular carcinoma : a report of the international consensus group for hepatocellular neoplasia. Hepatology 49 ; 658-664, 2009
7) 工藤正俊, 國分茂博編 : EOB-MRI/Sonazoid超音波による肝癌の診断と治療. 医学書院, 2013
8) 中沼安二 : 肝臓を診る医師のための肝臓病理テキスト. 南江堂, 2013
9) Theise ND, Nakanuma Y, Park YN, et al. : Combined hepatocellular-cholangiocarcinoma. WHO classification of tumours of the digestive system, 4 th ed, Lyon : IARC ; pp 225-227, 2010
P.92 掲載の参考文献
1) 日本肝臓学会 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
2) 日本肝臓学会編 : 肝癌診療マニュアル 第2版, 医学書院, 2010
3) Pugh RN, Murray-Lyon IM, Dawson JL, et al. : Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 ; 646-649, 1973
4) A new prognostic system for hepatocellular carcinoma : a retrospective study of 435 patients : the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 ; 751-755, 1998
5) Kudo M, Chung H, Osaki Y : Prognostic staging system for hepatocellular carcinoma (CLIP score) : its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38 ; 207-215, 2003
6) Christensen E, Schlichting P, Fauerholdt L, et al. : Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 4 ; 430-435, 1984
P.99 掲載の参考文献
1) 幕内雅敏, 高山忠利, 山崎晋, 他 : 肝硬変合併肝癌治療のStrategy. 外科治療 29 ; 1530-1536, 1987
2) Lau H, Man K, Fan ST, et al. : Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 84 ; 1255-1259, 1997
3) Hemming AW, Schudamore CH, Shackeleton CR, et al. : Indocyanine green clearance as a predictor of successful hepatic resection in cirrhotic patients. Am J Surg 163 ; 515-518, 1992
4) Nonami T, Nakao A, Kurokawa T, et al. : Blood loss and ICG clearance as best prognostic markers of post hepatectomy liver failure. Hepatogastroenterology 46 ; 1669-1672, 1999
5) Hsia CY, Lui WY, Chau GY, et al. : Perioperative safety and prognosis in hepatocellular carcinoma patients with impaired liver function. J Am Coll Surg 190 ; 574-579, 2000
6) Yokoyama Y, Nishio H, Ebata T, et al. : Value of indocyanine green clearance of the future liver remnant in predicting outcorne after resection for biliary cancer. Br J Surg 97 ; 1260-1268, 2010
7) Imamura H, Seyama Y, Kokudo N, et al. : One thousand fifty six hepatectomies without mortality in 8 years. Arch Surg 138 ; 1198-1206, 2003
8) Yamanaka N, Okamoto E, Oriyama T, et al. : A prediction scoring system to select the surgical treatment of liver cancer : Further refinement based on 10 years of use. Ann Surg 219 ; 342-346, 1994
9) Kubota K, Makuuchi M, Kusaka K, et al. : Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26 ; 1176-1181, 1997
10) Poon RT, Fan ST : Liver resection in cirrhosis of the liver. Surgery of the Liver, Biliary Tract and Pancreas, Forth edition, by Blumgart LH, Saunders, Philadelphia, p 1427-1439, 2007
11) Sawamura T, Kawasato S, Tsuda M, et al. : Clinical application of the measurement of serum asialoglycoproteins to estimate residual liver function in patients with chronic liver disease with or without hepatocellular carcinoma. Gastroenterol Jpn 20 ; 201-208, 1985
12) Ha-Kawa SK, Tanaka Y : A quantitative model of technetium- 99 m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor. J Nucl Med 32 ; 2233-2240, 1991
13) Yoshida M, Shiraishi S, Sakaguchi F, et al. : A quantitative index measured on 99 mTc GSA SPECT/CT 3D fused images to evaluate severe fibrosis in patients with chronic liver disease. Jpn J Radiol 30 ; 435-441, 2012
P.104 掲載の参考文献
1) 有井滋樹 : 肝癌早期発見を目的とした分子マーカーおよび画像診断システムの開発 厚生労働科学研究費補助金 肝炎等克服緊急対策研究事業 平成20年度-平成22年度 総合研究報告書, 2011
2) 有井滋樹, 松井修監・編集 : 肝細胞癌の早期診断 : 画像と分子マーカー. アークメディア, 2012
P.106 掲載の参考文献
1) Tajima T, Takao H, Akai H, et al. : Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced agnetic resonance imaging. J Comput Assist Tomogr 34 ; 362-366, 2010
2) 日本腎臓学会, 日本医学放射線学会, 日本循環器学会 : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2012. 東京医学社, 2012 (各学会のウェブサイトでも閲覧可能)
3) NSFとガドリニウム造影剤使用に関する合同委員会 (日本医学放射線学会・日本腎臓学会) : 腎障害患者におけるガドリニウム造影剤使用に関するガイドライン (第2版 : 2009年改訂). (各学会のウェブサイトで閲覧可能)
4) European Society of Urogenital Radiology : ESUR guidelines on contrastmedia (version 8.1). (http://www.esur.org/esur-guidelines/)
P.113 掲載の参考文献
1) 日本医学放射線学会, 日本放射線科専門医会・医会編 : 肝海綿状血管腫の画像診断ガイドライン 2007年版. 2007
2) Tsurusaki M, Kawasaki R, Yamaguchi M, et al. : Atypical hemangioma mimicking hepatocellular carcinoma with a special note on radiological and pathological findings. Jpn J Radiol 27 ; 156-160, 2009
3) Ueda K, Matsui O, Kawamori Y, et al. : Differentiation of hypervascular hepatic pseudolesions from hepatocellular carcinoma : value of single-level dynamic CT during hepatic arteriography. J Comput Assist Tomogr 22 ; 703-708, 1998
4) Tsurusaki M, Sugimoto K, Fujii M, et al. : Combination of CT during arterial portography and double-phase CT hepatic arteriography with multi-detector row helical CT for evaluation of hypervascular hepatocellular carcinoma. Clin Radiol 62 ; 1189-1197, 2007
5) Motosugi U, Ichikawa T, Sou H, et al. : Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256 ; 151-158, 2010
6) Nakashima O, Kurogi M, Yamaguchi R, et al. : Unique hypervascular nodules in alcoholic liver cirrhosis : identical to focal nodular hyperplasia-like nodules? J Hepatol 41 ; 992-998, 2004
7) Bosman FT, Hruban RH, Theise ND : WHO Classification of Tumours of the Digestive System. IARC, Lyon, 2010
8) Kim SA, Lee JM, Lee KB, et al. : Intrahepatic mass-forming cholangiocarcinomas : enhancement patterns at multiphasic CT, with special emphasis on arterial enhancenlent pattern--correlation with clinicopathologic findings. Radiology 260 ; 148-157, 2011
P.119 掲載の参考文献
1) Kojiro M, Okudaira S, Nakashima O : Clinicopathologic characteristics of focal nodular hyperplasia (FNH) of the liver. J Hep Bil Pancr Surg 3 ; 106-110, 1996
2) Bioulac-Sage P, Balabaud C, Wanless I : Focal nodular hyperplasia and hepatocellular adenoma. WHO classification of tumours of the digestive system. 198-204, IARC, Lyon, 2010
3) Nakashima O, Kurogi M, Yamaguchi R, et al. : Unique hypervascular nodules in alcoholic liver cirrhosis : indentical to focal nodular hyperplasia-like nodules? J Hepatol 41 ; 992-998, 2004
4) 特集 ; 肝細胞癌との鑑別を要する良性腫瘤-画像と病理. 消化器画像 3 (1), 2001
5) Sasaki M, Matsubara T, Kakuda Y, et al. : Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol 38 ; 364-369, 2014
6) Ishak KG, Goodman ZD, Stocker JT : Tumors of the liver and intrahepatic bile duct. Atlas of tumor pathology, Third series Fascicle 31
7) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版), 金原出版, 2009
8) 中島収, 田口順, 隈部力, 他 : 混合型肝癌の画像と病理 消化器画像 5 ; 491-498, 2003
9) Theise ND, Nakashima O, Park Y, et al. : Tumours of the liver and intrahepatic bile ducts ; Combined hepatocellular-cholangiocarcinoma. WHO classification of tumours of the digestive system. p 225-227, IARC, Lyon, 2010
P.124 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
2) Yoon YJ, Han KH, Kim do Y : Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 44 ; 861-866, 2009
3) 日本肝臓学会編 : 肝癌診療マニュアル (第2版). 医学書院, 2010
4) Tateishi R, Yoshida H, Matsuyama Y, et al. : Diagnostic accuracy of tumor markers for hepatocellular carcinoma : a systematic review. Hepatol Int 2 ; 17-30, 2008
5) Imai Y, Tamura S, Tanaka H, et al. : Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat 17 ; 185-91, 2010
6) Chen JD, Yang HI, Iloeje UH, et al. : Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138 ; 1747-1754, 2010
P.132 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, p. 12-15, 2013
2) Bruix J, Sherman M : Management of hepatocellular carcinoma : an up date. Hepatology 53 ; 1020-1022, 2011
3) EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma. J Hepatol 56 ; 908-943, 2012
4) Matsui O, Kobayashi S, Sanada J, et al. ; Hepatocelluar nodules in liver cirrhosis : hemodynamic evaluation (angiographyassiste CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36 ; 264-272, 2011
5) International Consensus Group for Hepatocellular Neoplasia : Pathologic diagnosis of early hepatocellular carcinoma : a report of the international consensus group for hepatocellular neoplasia. Hepatology 49 ; 658-664, 2009
6) Roskams T : Anatomic pathology impact on prognosis and response to therapy. Clin Liver Dis 15 ; 245-259, 2011
7) Van Beers BE, Pastor CM, Hussain HK : Primovist, Eovist : What to expect? J Hepatol 57 ; 421-429, 2012
8) WHO Classification of Tumors of the Digestive System. Edited by Bosman FT, Carneiro F, Hruban RH, et al. : IARC, Lyon, 2010, p 196-261
9) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, p. 15-27, 2009
10) Forner A, Llovet JM, Bruix J : Hepatocellular carcinoma. Lancet 379 ; 1245-1255, 2012
11) Llovet JM, Bru C, Bruix J : Prognosis of hepatocellular carcinoma : The BCLC staging classification. Semin Liver Dis 19 ; 329-338, 1999
12) Bruix J, Gores GJ, Mazzaferro V : Hepatocellular carcinoma : clinical frontiers and perspectives. Gut 63 ; 844-855, 2014
P.138 掲載の参考文献
1) 日本肝癌研究会追跡調査委員会 : 第19回 全国原発肝癌追跡調査報告 (2006~2007).
2) 日本肝癌研究会 編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
3) Burt AD, Portmann BC, Ferrell LD : MacSween's Pathology of the Liver. Elsevier Health Sciences, 2011
4) Honda H, Onitsuka H, Yasumori K, et al. : Intrahepatic peripheral cholangiocarcinoma : two-phased dynamic incremental CT and pathologic correlation. J Comput Assist Tomogr 17 ; 397-402, 1993
5) Maetani Y, Itoh K, Watanabe C, et al. : MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 176 ; 1499-1507, 2001
6) 波多野悦朗ほか : 肝内胆管癌におけるPET/CTの意義. 日消誌 109 ; 1878-1884, 2012
7) Kim SJ, Lee JM, Han JK, et al. : Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol 189 ; 1428-1434, 2007
8) Nakanuma Y, Curado M-P, Franceschi S, et al. : Intrahepatic cholangiocarcinoma. World Health Organization, 2010
9) 日本肝胆膵外科学会編 : 胆道癌取扱い規約 (第6版), 金原出版, 2013
10) Motosugi U, Ichikawa T, Nakajima H, et al. : Cholangiolocellular carcinoma of the liver : imaging findings. J Comput Assist Tomogr 33 ; 682-688, 2009
11) Buetow PC, Buck JL, Pantongrag-Brown L, et al. : Biliary cystadenoma and cystadenocarcinoma : clinical-imaging-pathologic correlations with emphasis on the importance of ovarian stroma. Radiology 196 ; 805-810, 1995
12) Tsui WMS, Adsay NV, Crawlord JM, et al. : Mucinous cystic neoplasm of the liver. World Health Organization, 2010
13) Fukukura Y, Taguchi J, Nakashima O, et al. : Combined hepatocellular and cholangiocarcinoma : correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 21 ; 52-58, 1997
14) Nishie A, Yoshimitsu K, Asayama Y, et al. : Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT : comparison with histologic findings. AJR Am J Roentgenol 184 ; 1157-1162, 2005
P.144 掲載の参考文献
1) Theise ND, Nakashima O, Park YN, et al. : Combined hepatocellular-cholangiocarcinoma. In : Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World health organization classification of tumors. WHO classification of tumors of the digestive system. Lyon, IARC, p. 225-227, 2010
2) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
3) Steiner PE, Higginson J : Cholangiolocellular carcinoma of the liver. Cancer 12 ; 753-759, 1959
4) Komuta M, Spee B, Vander Borght S, et al. : Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47 ; 1544-1556, 2008
5) 中野雅行 : 細胆管細胞癌の病理組織学的特徴. 胆と膵 25 ; 343-349, 2004
6) Maeno S, Kondo F, Sano K, et al. : Morphometric and immunohistochemical study of cholangiolocellular carcinoma : comparison with non-neoplastic cholangiole, interlobular duct and septal duct. J Hepatobiliary Pancreat Sci 19 ; 289-296, 2012
7) 日本肺癌学会編 : 肺癌取扱い規約 (第7版). 金原出版, 2010

III. 治療編

P.151 掲載の参考文献
1) 杉浦信之, 高良健司, 大藤正雄, 他 : 超音波映像下経皮的腫瘍内エタノール注入による小肝細胞癌の治療. 肝臓 24 ; 920, 1983
2) Shiina S, Tateishi R, Imamura M, et al. : Percutaneous ethanol injection for hepatocellular carcinoma : 20-year outcome and prognostic factors. Liver Int 32 ; 1434-1442, 2012
3) Lin SM, Lin CJ, Lin CC, et al. : Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma <or=4 cm. Gastroenterology 127 ; 1714-1723, 2004
4) Shiina S, Teratani T, Obi S, et al. : A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 ; 122-130, 2005
5) Shiina S, Tateishi R, Arano T, et al. : Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors. Am J Gastroenterol 107 ; 569-577, 2012
6) 日本肝癌研究会 (編) : 第18回全国原発性肝癌追跡調査報告. 2009
7) Mulier S, Mulier P, Ni Y, et al. : Complications of radiofrequency coagulation of liver tumours. Br J Surg 89 ; 1206-1222, 2002
8) 春日井博志, 大崎往夫, 岡博子, 他 : 多施設 (38施設) 調査に基づくラジオ波治療の現状と問題点. 肝臓 44 ; 632-40, 2003
9) 椎名秀一朗, 佐藤隆久, 近藤祐嗣, 他 : 大腸癌の多発肝転移に対する治療戦略 ラジオ波焼灼療法 (RFA) 10年間の成績と今後の展開. 日外会誌 114 ; 107-111, 2013
P.158 掲載の参考文献
1) Nakazawa T, Kokubu S, Shibuya S, et al. : Radiofrequency ablation of hepatocellular carcinoma : correlation between local tumor progression after ablation and ablative margin. Am J Roentgenol 188 ; 480-488, 2007
2) Berber E, Flesher NL, Siperstein AE : Initial clinical evaluation of the RITA 5-centimeter radiofrequency thermal ablation catheter in the treatment of liver tumors. Cancer J 6 ; 319-329, 2000
3) Kobayashi M, Ikeda K, Someya T, et al. : Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma. Oncology 63 ; 139-144, 2002
4) 日高央, 國分茂博, 細谷聡子, 他 : 経皮的ラジオ波熱凝固療法時の工夫-穿刺針が描出困難時のair beamの活用-. Rad Fan 4 ; 104-106, 2006
5) Osaki Y, Ikeda K, Okita K, et al. : Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers. J Gastroenterol 48 ; 1308-1309, 2013
P.161 掲載の参考文献
1) Kim PN, Choi D, Rhim H, et al. : Planning ultrasound for percutaneous radiofrequency ablation to treat small (? 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging : a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol 23 ; 627-634, 2012
2) Lee MW, Rhim H, Cha DI, et al. : Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1-3 cm) : value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol 24 ; 958-965, 2013
3) Masuzaki R, Shiina S, Tateishi R, et al. : Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol 26 ; 759-764, 2011
4) Lim S, Lee MW, Rhim H, et al. : Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol 25 ; 307-314, 2014
5) Takaki H, Yamakado K, Nakatsuka A, et al. : Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images. Int J Clin Oncol 18 ; 46-53, 2013
6) Yamakado K, Nakatsuka A, Akeboshi M, et al. : Percutaneous radiofrequency ablation of liver neoplasms adjacent to the gastrointestinal tract after balloon catheter interposition. J Vasc Interv Radiol 14 (9 Pt 1) : 1183-1186, 2003
7) Hasegawa T, Takaki H, Miyagi H, et al. : Hyaluronic acid gel injection to prevent thermal injury of adjacent gastrointestinal tract during percutaneous liver radiofrequency ablation. Cardiovasc Intervent Radiol 36 ; 1144-1146, 2013
8) Choi BI, Park JH, Kim BH, et al. : Small hepatocellular carcinoma : detection with sonography, computed tomography (CT), angiography and Lipiodol-CT. Br J Radiol 62 ; 897-903, 1989
9) Rizvi S, Camci C, Yong Y, et al. : Is post-Lipiodol CT better than i.v. contrast CT scan for early detection of HCC? A single liver transplant center experience. Transplant Proc 38 ; 2993-2995, 2006
P.166 掲載の参考文献
1) Imamura H, Matsuyama Y, Tanaka E, et al. : Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 ; 200-207, 2003
2) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
3) 西島規浩, 大崎往夫, 喜多竜一, 他 : 肝細胞癌に対するRFAにおける効果判定基準の提唱-局所再発率の検討から-. 肝臓 49 : 192-199, 2008
4) Nishikawa H, Inuzuka T, Takeda H, et al. : Percutaneous radiofrequency ablation therapy for hepatocellularcarcinoma : a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 46 ; 1418-1426, 2011
5) Nishikawa H, Osaki Y, Iguchi E, et al. : Radiofrequency ablation for hepatocellular carcinoma : the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 48 ; 951-965, 2013
6) 池田敦之, 木村達, 坂本梓, 他 : ソナゾイド造影超音波による肝細胞癌のRFA 後治療効果判定-造影CTとの比較-. 肝臓 50 ; 18-25, 2009
7) Okubo H, Kokubu S, Komiyama M, et al. : Radiofrequency ablation of hepatocellular carcinoma : The feasibility of magnetic resonance imaging with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid for evaluating the ablative margin. Hepatol Res 40 ; 1034-1041, 2010
P.171 掲載の参考文献
1) Yamada R, Sato M, Kawabata M, et al. : Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148 ; 397-401, 1983
2) Ekelund L, Lin G, Jeppsson B : Blood supply of experimental liver tumors after intraarterial embolization with Gelfoam powder and absolute ethanol. Cardiovasc Intervent Radiol 7 ; 234-239, 1984
3) Miyayama S, Yamashiro M, Hashimoto M, et al. : Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma < 6cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. Cardiovasc Intervent Radiol 37 ; 388-395, 2014
4) Takayasu K, Arii S, Kudo M, et al. : Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 56 ; 886-892, 2012
5) Yamakado K, Miyayama S, Hirota S, et al. : Hepatic arterial embolization for unresectable hepatocellular carcinomas : do technical factors affect prognosis? Jpn J Radiol 30 ; 560-566, 2012
6) Takaki S, Sakaguchi H, Anai H, et al. : Long-term outcome of transcatheter subsegmental and segmental arterial chemoembolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol 35 ; 544-554, 2012
7) 宮山士朗 : 肝細胞癌に対する肝動脈化学塞栓療法の現状と今後の展望. 京府医大誌 121 ; 313-322, 2012
8) Yodono H, Matsuo K, Shinohara A : A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs 22 : 277-282, 2011
9) Miyayama S, Yamashiro M, Shibata Y, et al. : Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol 30 ; 263-70, 2012
10) Miyayama S, Yamashiro M, Hashimoto M, et al. : Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol 24 ; 501-508, 2013
P.176 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版, 金原出版, 2013
2) Takaki S, Sakaguchi H, Anai H, et al. : Long-term outcome of transcatheter subsegmental and segmental arterial chemoembolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol 35 ; 544-554, 2012
3) Miyayama S, Matsui O, Yamashiro M, et al. : Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas : Relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 18 ; 365-376, 2007
4) Miyayama S, Yamashiro M, Hashimoto M, et al. : Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma < 6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. Cardiovasc Intervent Radiol 37 ; 388-395, 2014
5) Kawamura Y, Ikeda K, Hirakawa M, et al. : Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 39 ; 346-354, 2009
6) Hanada M, Baba A, Tsutsumishita Y, et al. : Intrahepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by including platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 64 ; 473-483, 2009
7) Imai Y, Chikayama T, Nakazawa M, et al. : Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol 47 ; 179-186, 2012
8) Watanabe S, Nitta N, Ohta S, et al. : Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol 35 ; 399-405, 2012
9) Iwasawa J, Hashimoto N, Ohue S, et al. : Chemoembolization-induced arterial damage : Evaluation of three different chemotherapeutic protocols using epirubicin and miriplatin. Hepatol Res 44 ; 201-208, 2014
10) 高良真一, 東原秀行, 浦川博史, 他 : ミリプラチンリピオドール懸濁液の加温効果. 新薬と臨 60 ; 146-150, 2011
11) Kora S, Urakawa H, Mitsufuji T, et al. : Warming effect of miliplatin-lipodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma : preliminary clinical experience. Cardiovasc Intervent Radiol 36 ; 1023-1029, 2013
12) Seko Y, Ikeda K, kawamura Y, et al. : Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 43 ; 942-949, 2013
13) Okusaka T, Okada S, Nakanishi T, et al. : Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 22 ; 169-176, 2004
14) Iwasawa J, Hashimoto N, Ohue S, et al. : Initial safety and outcomes of miriplatin plus low-dose epirubicin for transarterial chemoembolization for hepatocellular carcinoma. Anticancer Res 32 ; 5039-5044, 2012
15) Irie T, Kuramochi M, Takahashi N : Dence accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization : measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 36 ; 706-713, 2013
16) 入江俊之, 倉持正志, 高橋信幸 : B-TACE : Ultra-selective TACEとの対比. IVR会誌 28 ; 436-442, 2013
17) 新井弘隆, 小林剛, 長島多聞, 他 : ミリプラチンを用いたマイクロバルーン閉塞下肝動脈化学塞栓療法 (B-TACE) の初期経験. 肝臓 54 : 81-83, 2013
P.181 掲載の参考文献
1) Laurent A, Beaujeux R, Wassef M, et al. : Trisacryl gelatin microsphea for therapeutic embolization, I : development and in vitro evakuation. AJNR Am J Neuroradiol 17 ; 533-540, 1996
2) Maluccio MA, Covey AM, Porat LB, et al. : Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19 ; 862-869, 2008
3) Malagari K, Pomoni M, Kelekis A, et al. : Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33 ; 541-551, 2010
4) Lammer J, Malagari K, Vogl T, et al. : Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study. Cardiovasc Intervent Radiol 33 ; 41-52, 2010
5) Golfieri R, Giampalma E, Renzulli M, et al. : Randomized controlled trial of doxorubicin-eluting beads vs conventional chemoemboloization for hepatocellular carcinoma. Br J Cancer 111 ; 255-264, 2014
6) Burrel M, Reig M, Forner A, et al. : Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 56 ; 1330-1335, 2012
P.187 掲載の参考文献
1) Yeo W, Mok TS, Zee B, et al. : A randomized phase III study of doxorubicin versus cisplatin/interferon alpha- 2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 ; 1532-1538, 2005
2) Kaseb AO, Shindoh J, Patt YZ, et al. : Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 119 ; 3334-3342, 2013
3) Qin S, Bai Y, Lim HY, et al. : Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from asia. J Clin Oncol 31 ; 3501-3508, 2013
4) Nagamatsu H, Hiraki M, Mizukami N, et al. : Intraarterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 32 ; 543-550, 2010
5) Nouso K, Miyahara K, Uchida D, et al. : Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 109 ; 1904-1907, 2013
6) Ueshima K, Kudo M, Takita M, et al. : Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 78 Suppl 1 : 148-153, 2010
7) 浦山直樹, 山崎隆弘, 播磨陽平, 他 : 進行肝細胞癌に対する肝動注化学療法114例の検討. 肝臓 52 ; 449-460, 2011
8) Yamashita T, Kaneko S : Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 109 ; 1335-1345, 2012
9) Obi S, Yoshida H, Toune R, et al. : Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106 ; 1990-1997, 2006
10) Nagano H, Wada H, Kobayashi S, et al. : Long-term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 80 ; 63-69, 2011
11) Yamashita T, Arai K, Sunagozaka H, et al. : Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 81 ; 281-290, 2011
12) Monden M, Sakon M, Sakata Y, et al. : 5-fluorouracil arterial infusion+interferon therapy for highly advanced hepatocellular carcinoma : A multicenter, randomized, phase II study. Hepatol Res 42 ; 150-165, 2012
13) Chung YH, Song IH, Song BC, et al. : Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88 ; 1986-1991, 2000
14) Iwasa S, Ikeda M, Okusaka T, et al. : Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 41 ; 770-775, 2011
P.195 掲載の参考文献
1) Wilhelm SM, Carter C, Tang L, et al. : BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 ; 7099-7109, 2004
2) Liu L, Cao Y, Chen C, et al. : Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66 ; 11851-11858, 2006
3) Llovet JM, Ricci S, Mazzaferro V, et al. : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390, 2008
4) Cheng AL, Kang YK, Chen Z, et al. : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 ; 25-34, 2009
5) Furuse J, Ishii H, Nakachi K, et al. : Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99 ; 159-165, 2008
6) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
7) 日本肝臓学会編 : 肝癌診療マニュアル 第2版. 医学書院, 2010
8) Ueshima K, Kudo M, Takita M, et al. : Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 29 ; 321-325, 2011
P.197 掲載の参考文献
1) Kudo M, Imanaka K, Chida N, et al. : Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47 ; 2117-2127, 2011
2) Lencioni R, Zou J, Leberre M, et al. : Sorafenib or placebo in combination with transarterial chemoembolization for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol (28 : Abstract TPS178), 2010
3) Hagihara A, Ikeda M, Ueno H, et al. : Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 105 ; 354-358, 2014
4) Ueshima K, Kudo M, Tanaka M, et al. : Phase I study of Sorafenib in combination with lowdose cisplatin and flurouracil intra-arterilal infusion chemotherapy. The 9th Annual Meeting of Japanese Society of Medical Oncology, Yokohama, Japan, July 21-23, 2011 (Abstract IS-3-2)
P.201 掲載の参考文献
1) Abou-Alfa GK, Schwartz L, Ricci S, et al. : Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 ; 4293-4300, 2006
2) Lencioni R, Llovet JM : Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 ; 52-60, 2010
3) 田中正俊 : 肝動注化学療法の効果判定. 日本肝臓学会編. 肝癌診療マニュアル. 医学書院, 2010 ; 134-135
4) Llovet JM, Ricci S, Mazzaferro V, et al. : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390, 2008
5) Cheng AL, Kang YK, Chen Z, et al. : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 ; 25-34, 2009
6) Arizumi T, Ueshima K, Takeda H, et al. : Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol. 2014. [Epub ahead of print]
P.204 掲載の参考文献
1) Ikeda K, Kumada H, Kudo M, et al. : Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients (Pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol 23 : 2012 (supple 9 ; abstr 737P)
2) Kudo M, Imanaka K, Chida N, et al. : Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47 ; 2117-2127, 2011
3) Rimassa L, Porta C, Borbath I, et al. : Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy : Results of a randomized controlled phase II tria (l RCT). J Clin Oncol 30 : 2012 (suppl ; abstr 4006).
4) Verslype C, Cohn AL, Kelley RK, et al. : Activity of cabozantinib (XL184) in hepatocellular carcinoma : Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30 : 2012 (suppl ; abstr 4007)
P.210 掲載の参考文献
1) 上本伸二 : 肝癌に対する肝臓移植のベストプラクティス. 日消誌 111 : 875-879, 2014
2) Ikai I, Arii S, Okazaki M, et al. : Report of the 17 th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res. 37 ; 679-691, 2007
3) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン (2013年版). 金原出版, 2013
4) Bruix J, Raoul JL, Sherman M, et al. : Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : subanalyses of a phase III trial. J Hepatol 57 ; 821-829, 2012
5) Ikai I, Hatano E, Hasegawa S, et al. : Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg 202 ; 431-438, 2006
6) Hasegawa K, Takayama T, Ijichi M, et al. : Uracil-tegafur as an adjuvant for hepatocellular carcinoma : a randomized trial. Hepatology 44 ; 891-895, 2006
P.214 掲載の参考文献
P.219 掲載の参考文献
P.226 掲載の参考文献
1) 日本肝移植研究会 : 肝移植症例登録報告. 移植 46 ; 524-536, 2012
2) Mazzaferro V, Regalia E, Doci R, et al. : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 ; 693-699, 1996
15) Taketomi A, Sanefuji K, Soejima Y, et al. : Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 87 ; 531-537, 2009
16) Singal AK, Guturu P, Hmoud B, et al. : Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95 ; 755-760, 2013
17) Adam R, Karam V, Delvart V, et al. : Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57 ; 675-688, 2012
18) Shirabe K, Itoh S, Yoshizumi T, et al. : The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 95 ; 235-240, 2007
19) Duvoux C, Roudot-Thoraval F, Decaens T, et al. : Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 143 ; 986-994, 2012
20) Liang W, Wang D, Ling X, et al. : Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma : a meta-analysis. Liver Transpl 18 ; 62-69, 2012
21) Maggs JR, Suddle AR, Aluvihare V, et al. : Systematic review : the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 35 ; 1113-1134, 2012
22) Welker MW, Bechstein WO, Zeuzem S, et al. : Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 26 ; 109-118, 2013
23) Sugawara Y, Tamura S, Yamashiki N, et al. : Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation. Transplant Proc 44 ; 791-793, 2012
P.231 掲載の参考文献
1) 日本肝移植研究会 : 肝移植症例登録報告. 移植 47 ; 416-428, 2012
2) Akabayashi A, Slingsby BT, Fujita M : The first donor death after living-related liver transplantation in Japan. Transplantaion 77 ; 634, 2004
3) Hatta T, Fujinaga Y, Kadoya M, et al. : Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging : a prospective study in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol 45 ; 1263-1271, 2010
4) 日本肝移植研究会 : 肝移植症例登録報告 (第1報). 移植 48 ; 362-368, 2013
P.235 掲載の参考文献
1) 市田隆文, 玄田拓哉, 平野克治 : 脳死肝移植の現状と展望. 内科 109 ; 444-448, 2012
2) 市田隆文 : 脳死肝移植適応評価委員会はどう変わったか. 肝胆膵 63 ; 87-91, 2011
3) 日本肝移植研究会 : 肝移植症例登録報告. 移植 47 ; 416-428, 2012
4) 市田隆文 : わが国における肝細胞癌に対する肝移植の現状. Liver Cancer J 95 ; 190-195, 2013
5) 市田隆文, 玄田拓哉, 平野克治 : 脳死肝移植 (2) 今後の展望, 臨消内科 28 ; 1233-1239, 2013
P.239 掲載の参考文献
1) Watashi K, Hijikata M, Hosaka M, et al. : Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38 ; 1282-1288, 2003
2) Rabie R, Mumtaz K, Renner EL : Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus : a systematic review and meta-analysis. Liver Transpl 19 ; 36-48, 2013
3) Samonakis DN, Germani G, Burroughs AK : Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 56 ; 973-983, 2012
4) Ueda Y, Kaido T, Ito T, et al. : Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation 97 ; 344-350, 2014
5) Ueda Y, Yoshizawa A, Y Ogura, et al. : Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res in press
6) Garg V, Heeswijk R, Lee JE, et al. : Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 54 ; 20-27, 2011
7) Kikuchi M, Okuda Y, Ueda Y, et al. : Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the japanese liver transplant patients. Biol Pharm Bull 37 ; 417-423, 2014
8) Pungpapong S, Aqel BA, Koning L, et al. : Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 19 ; 690-700, 2013
9) Coilly A, Roche B, Dumortier J, et al. : Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation : a multicenter experience. J Hepatol 60 ; 78-86, 2014
P.243 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2009年版. 金原出版, 2009
2) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
3) Cheng JC, Wu JK, Lee PC, et al. : Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60 : 1502-1509, 2004
4) Klein J, Dawson LA : Hepatocellular carcinoma radiation therapy : review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87 ; 22-32, 2013
5) Meng MB, Cui YL, Lu Y, et al. : Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma : a systematic review and meta-analysis. Radiother Oncol 92 ; 184-194, 2009
6) Dawson LA, Ten Haken RK : Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15 ; 279-283, 2005
7) Louis C, Dewas S, Mirabel X, et al. : Stereotactic radiotherapy of hepatocellular carcinoma : preliminary results. Technol Cancer Res Treat 9 ; 479-487, 2010
8) Andolino DL, Johnson CS, Maluccio M, et al. : Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81 ; 447-453, 2011
9) 肝細胞癌に対する体幹部定位放射線治療. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000009993&language=J accessed on 15 Feb, 2014.
10) Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer (RTOG 1112). http://clinicaltrials.gov/show/NCT01730937. accessed on 15 Feb, 2014.
P.247 掲載の参考文献
1) Kato H, Tsujii H, Miyamoto T, et al. : Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59 ; 1468-1476, 2004
2) Kawashima M, Furuse J, Nishio T, et al. : Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23 ; 1839-1846, 2005
3) Fukumitsu N, Sugahara S, Nakayama H, et al. : A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat oncol biol Phys 74 ; 831-836, 2009
4) Bush DA, Hillebrand DJ, Slater JM, et al. : High-dose proton beam radiotherapy of hepatocellular carcinoma : preliminary results of a phase II trial. Gastroenterology 127 ; S 189-93, 2004
5) Chiba T, Tokuuye K, Matsuzaki Y, et al. : Proton beam therapy for hepatocellular carcinoma : a retrospective review of 162 patients. Clin Cancer Res 11 : 3799-3805, 2005
6) Komatsu S, Fukumoto T, Demizu Y, et al. : Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 117 ; 4890-4904, 2011
7) Mizumoto M, Tokuuye K, Sugahara S, et al. : Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys 71 ; 462-467, 2008
8) Mizumoto M, Okumura T, Hashimoto T, et al. : Proton beam therapy for hepatocellular carcinoma : a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81 ; 1039-1045, 2011
9) Sugahara S, Oshiro Y, Nakayama H, et al. : Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 76 : 460-466, 2010
10) Komatsu S, Fukumoto T, Demizu Y, et al. : The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Gastroenterol 46 ; 913-920, 2011
P.252 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
2) Tandon P, Garcia-Tsao G : Prognostic indicators in hepatocellular carcinoma : a systematic review of 72 studies. Liver Int 29 ; 502-510, 2009
3) Mazzaferro V, Regalia E, Doci R, et al. : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 ; 693-699, 1996
4) Ishii H, Okada S, Nose H, et al. : Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77 ; 1792-1796, 1996
5) Shiina S, Tateishi R, Arano T, et al. : Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors. Am J Gastroenterol 107 ; 569-577, 2012
6) Plessier A, Codes L, Consigny Y, et al. : Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 10 (2 Suppl 1) : S 86-90, 2004
7) Nakashima Y, Nakashima O, Tanaka M, et al. : Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 26 ; 142-147, 2003
8) Tateishi R, Shiina S, Yoshida H, et al. : Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44 ; 1518-1527, 2006
9) Enooku K, Tateishi R, Kanai F, et al. : Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. J Gastroenterol 47 ; 71-78, 2012
10) Fujiki M, Takada Y, Ogura Y, et al. : Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 9 ; 2362-2371, 2009
11) Malinchoc M, Kamath PS, Gordon FD, et al. : A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 ; 864-871, 2000
12) Uchino K, Obi S, Tateishi R, et al. : Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol 47 ; 1152-1159, 2012
P.254 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
2) Arii S, Yamaoka Y, Futagawa S, et al. : Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas : a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32 ; 1224-1229, 2000
3) Hasegawa K, Makuuchi M, Takayama T, et al. : Surgical resection vs. percutaneous ablation for hepatocellular carcinoma : A preliminary report of the Japanese nationwide survey. J Hepatol 49 ; 589-594, 2008
4) Wang Y, Luo Q, Li Y, et al. : Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas : a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 9 ; e84484, 2014
5) Hasegawa K, Kokudo N, Makuuchi M, et al. : Comparison of resection and ablation for hepatocellular carcinoma : A cohort study based on a Japanese nationwide survey. J Hepatol 58 ; 724-729, 2013
6) Nakashima Y, Nakashima O, Tanaka M, et al. : Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 26 ; 142-147, 2003
7) Nakayama H, Takayama T, Okubo T, et al. : Proposal of objective morphological classification system for hepatocellular carcinoma using preoperative multiphase computed tomography. J Gastroenterol. 2013 Nov 16. [Epub ahead of print].
P.258 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2009年版. 金原出版, 2009
2) Arii S, Sata M, Sakamoto M, et al. : Management of hepatocellular carcinoma : Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 40 ; 667-685, 2010
3) 日本肝臓学会編 : 肝癌診療マニュアル 第2版. 医学書院, 2010
4) Monden M, Sakon M, Sakata Y, et al. : 5-fluorouracil arterial infusion+interferon therapy for highly advanced hepatocellular carcinoma : A multicenter, randomized, phase II study. Hapatol Res 42 ; 150-165, 2012
5) Lammer J, Malagari K, Vogl T, et al. : Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study. Cardiovasc Intervent Radiol 33 ; 41-52, 2010
P.261 掲載の参考文献
1) Inoue Y, Hasegawa K, Ishizawa T, et al. : Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery 145 ; 9-19, 2009
2) Ban D, Shimada K, Yamamoto Y, et al. : Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg 13 ; 1921-1928. 2009
3) Fukumoto T, Tominaga M, Kido M, et al. : Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol 21 ; 971-978, 2014
4) Sugahara S, Oshiro Y, Nakayama H, et al. : Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 76 ; 460-466, 2010
5) Komatsu S, Fukumoto T, Demizu Y, et al. : The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Gastroenterol 46 ; 913-920, 2011
6) Peng ZW, Guo RP, Zhang YJ, et al. : Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 118 ; 4725-4736, 2012
7) 波多野悦朗, 瀬尾智, 石井隆道, 他 : 高度進行癌の外科治療. 肝・胆・膵 65 ; 1211-1217, 2012
P.265 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版, 金原出版, 2013
2) Wang W, Shi J, Xie WF : Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma : a meta-analysis. Liver Int 30 ; 741-749, 2010
3) Morimoto M, Numata K, Kondou M, et al. : Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma : a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatherter arterial chemoembolization. Cancer 116 ; 5452-5460, 2010
4) Shibata T, Isoda H, Hirakawa Y, et al. : Small hepatocellular carcinoma : Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252 ; 905-913, 2009
P.267 掲載の参考文献
1) N'Kontchou G, Mahamoudi A, Aout M, et al. : Radiofrequency ablation of hepatocellular carcinoma : long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50 ; 1475-1483, 2009
2) Taura K, Ikai I, Hatano E, et al. : Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection : an analysis of 610 patients over 16 years old. Ann Surg 244 ; 265-273, 2006
3) Poon RT, Ng IO, Fan ST, et al. : Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma : a study of a prospective cohort. J Clin Oncol 19 ; 3037-3044, 2001
4) Arii S, Tanaka J, Yamazoe Y, et al. : Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 69 ; 913-919, 1992
5) Toyoda H, Kumada T, Kiriyama S, et al. : Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4 ; 111-117, 2006
6) Shah SA, Cleary SP, Wei AC, et al. : Recurrence after liver resection for hepatocellular carcinoma : risk factors, treatment, and outcomes. Surgery 141 ; 330-339, 2007
7) Okuda K, Ohtsuki T, Obata H, et al. : Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 ; 918-928, 1985
8) A new prognostic system for hepatocellular carcinoma : a retrospective study of 435 patients : the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 ; 751-755, 1998
9) Kudo M, Chung H, Osaki Y : Prognostic staging system for hepatocellular carcinoma (CLIP score) : its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38 ; 207-215, 2003
10) Ikai I, Arii S, Okazaki M, et al. : Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 37 ; 676-691, 2007
11) Tateishi R, Yoshida H, Shiina S, et al. : Proposal of a new prognostic model for hepatocellular carcinoma : an analysis of 403 patients. Gut 54 ; 419-425, 2005
P.271 掲載の参考文献
1) Yamashita Y, Tsuijita E, Takeishi K, et al. : Predictors for microinvasion of small hepatocellular carcinoma < 2cm. Ann Surg Onco 19 ; 2027-2034, 2012
2) Taketomi A, Sanefuji K, Soejima Y, et al. : Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 87 ; 531-537, 2009
3) Shirabe K, Toshima T, Kimura K, et al, : New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int 34 : 937-941, 2014
P.278 掲載の参考文献
1) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
2) Forner A, Llovet JM, Bruix J : Hepatocellular carcinoma. Lancet 379 ; 1245-1255, 2012
3) Hasegawa K, Makuuchi M, Takayama T, et al. : Surgical resection vs percutaneous ablation for hepatocellular carcinoma : a preliminary report of the Japanese nationwide survey. J Hepato 49 ; 589-594, 2008
4) Hasegawa K, Kokudo N, Makuuchi M, et al. : Comparison of resection and ablation for hepatocellular carcinoma : a cohort study based on a Japanese nationwide survey. J Hepatol 58 ; 724-729, 2013
5) Murakami T, Ishimaru H, Sakamoto I, et al. : Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma : rate and risk factors for local recurrence. Cardiovascu Intervent Radiol 30 ; 696-704, 2007
6) Llovet JM, Real MI, Montana X, et al. : Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial. Lancet 359 ; 1734-1739, 2002
7) Llovet JM, Ricci S, Mazzaferro V, et al. : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 ; 378-390, 2008
8) Mazzaferro V, Regalia E, Doci R, et al. : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med 334 ; 693-699, 1996
9) Todo S, Fukuhara H, Tada M : Extending indication : role of living donor liver transplantation for hepatocellular carcinoma, Liver Transpl 13 ; S 48-54, 2007
10) Eddy DM : Clinical decision making : from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263 ; 3077, 3081, 3084, 1990
11) Ishizawa T, Hasegawa K, Aoki T, et al. : Neither multiple tumors nor portal hypertension are surgical contraindication for hepatocellular carcinoma. Gastroenterology 134 ; 1908-1916, 2008
12) Kitano K, Murayama T, Sakamoto M, et al. : Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg 41 ; 376-382, 2012
13) Hasegawa K, Makuuchi M, Kokudo N, et al. : Impact of histologically confirmed lymph node metastasis on patient survival after surgical resection for hepatocellular carcinoma : report of a Japanese nationwide survey. Ann Surg 259 ; 166-170, 2014
14) Takemura N, Hasegawa K, Aoki T, et al. : Surgical resection of peritoneal or thoracoabdominal wall implants from hepatocellular carcinoma. Br J Surg 101 ; 1017-1022, 2014
15) Inoue Y, Hasegawa K, Ishizawa T, et al. : Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery 145 ; 9-19, 2009
P.283 掲載の参考文献
1) 日本肝癌研究会 : 第18回 全国原発性肝癌追跡調査報告 (2004-2005)
2) Lee MH, Yang HI, Liu Y, et al. : Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients : risk scores integrating host and virus profiles. Hepatology 58 : 546-554, 2013
3) Hosaka T, Suzuki F, Kobayashi M, et al. : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 ; 98-107, 2013
4) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (第2版). 2014
5) Sohn W, Paik Y, Kim JM, et al. : HBA DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma. Ann Surg Oncol 2014 DOI 10.1245/s10434-014-3621-x
6) Miyake Y,Takaki A, Iwasaki Y, et al : Meta-analysis : interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17 : 287-292, 2010
7) Shimomura S, Ikeda N, Saito M, et al. : Long-term interferon therapy after radiofrequency ablation iseffective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 5 ; 559-566, 2011
8) Hirakawa M, Ikeda K, Arase Y, et al. : Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 47 ; 1637-1643, 2008
9) Asahina Y, Tsuchiya K, Izumi N, et al. : α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013 Epub ahead of print
10) Tanaka A, Uegaki S, Kurihara H, et al. : Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 13 ; 5180-5187, 2007
P.285 掲載の参考文献
1) Arase Y, Ikeda K, Murashima N, et al. : The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79 ; 1494-1500, 1997
2) Ikeda K, Arase Y, Kobayashi M, et al. : A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C : a cohort study of 1249 patients. Dig Dis Sci 51 ; 603-609, 2006
3) Veldt BJ, Hansen BJ, Ikeda K, et al. : Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 41 ; 1087-1094, 2006
4) Muto Y, Sato S, Watanabe A, et al. : Overweight and obesity increases the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 35 ; 204-214, 2006
5) Kobayashi M, Ikeda K, Arase Y, et al. : Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 43 ; 63-70, 2008
6) Kato J, Miyanishi K, Kobune M, et al. : Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 42 ; 830-836, 2007
7) Kakizaki S, Sohara N, Sato K, et al. : Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol 22 ; 518-522, 2007
8) Habu D, Shiomi S, Tamori A, et al. : Role of vitamin K2 in the development of hepatocellular carcinoma in women with vital cirrhosis of the liver. JAMA 292 ; 358-361, 2004
9) Nishino H : Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture. Recent Results Cancer Res 174 ; 67-71, 2007
10) Inoue M, Yoshimi I, Sobue T, et al. : Influence of coffee drinking on subsequent risk of hepatocellular carcinoma : a prospective study in Japan. J Natl Cancer Inst 97 ; 293-300, 2005
11) Kurozawa Y, Tamakoshi A : JACC Study Group : Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 93 ; 607-610, 2005
12) Muto Y, Moriwaki H, Ninomiya M, et al. : Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334 ; 1561-1567, 1996
13) Yoshiji H, Noguchi R, Toyohara M, et al. : Combination of vitamin K 2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 51 ; 315-521, 2009
P.289 掲載の参考文献
1) 日本肝臓学会編 : 肝癌診療マニュアル 第2版. 医学書院, 2010
2) 日本肝臓学会編 : 科学的根拠に基づく肝癌診療ガイドライン 2013年版. 金原出版, 2013
3) Llovet JM, Ricci S, Mazzaferro V, et al. : Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 359 ; 378-390, 2008
4) Cheng AL, Kang YK, Chen Z, et al. : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 ; 25-34, 2009
5) Tatebe H, Shimizu M, Shirakami Y, et al. : Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res 14 ; 2806-2812, 2008
6) 清水雅仁, 森脇久隆 : 肝臓癌化学予防 (2) レチノイドを中心に. 臨消内科 23 ; 1699-1706, 2008
7) Muto Y, Moriwaki H, Ninomiya M, et al. : Prevension of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334 ; 1561-1567, 1996
8) Muto Y, Moriwaki H, Saito A : Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340 : 1046-1047, 1999
9) Okita K, Matsui O, Kumada H, et al. : Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC) : Results of a phase II/III randomized placebo-controlled trial (Abstract 4024), ASCO, 2010
10) Okusaka T, Makuuchi M, Matsui H, et al. : Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor : A subgroup analysis in a phase II/III randomized, placebo-controlled trial. Meeting : 2011 Gastrointestinal Cancers Symposium, Abstract 165
P.295 掲載の参考文献
1) Taura N, Ichikawa T, Miyaaki H, et al. : Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit 19 ; 742-750, 2013
2) Taura N, Fukushima N, Yastuhashi H, et al. : The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit 17 ; 7-11, 2011
3) Ohki T, Tateishi R, Akahane M, et al. : CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients : a randomized controlled trial. Am J Gastroenterol 108 ; 1305-1313, 2013
4) Yoshida H, Shiratori Y, Moriyama M, et al. : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 ; 174-181, 1999
5) Tateishi R, Shiina S, Yoshida H, et al. : Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 44 ; 1518-1527, 2006
6) Nanashima A, Taura N, Abo T, et al. : Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci 56 : 3086-3100, 2011
P.298 掲載の参考文献
1) 日本肝癌研究会 : 第18回全国原発性肝癌追跡調査報告 (2004-2005). 肝臓 51 ; 460-484, 2010
2) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版). 金原出版, 2009
3) Yedibela S, Demir R, Zhang W, et al. : Surgical treatment of mass-forming intrahepatic cholangiocarcinoma : an 11-year Western single-center experience in 107 patients. Ann Surg Oncol 16 ; 404-412, 2009
4) Uenishi T, Kubo S, Yamazaki O, et al. : Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 15 ; 417-422, 2008
5) Yamamoto M, Ariizumi S, Otsubo T, et al. : Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma. J Surg Oncol 87 ; 80-83, 2004
6) Choi SB, Kim KS, Choi JY, et al. : The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection : association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 16 ; 3048-3056, 2009
7) Uchiyama K, Yamamoto M, Yamaue H, et al. : Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma : a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 18 ; 443-452, 2011
8) Inoue K, Makuuchi M, Takayama T, et al. : Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 127 ; 498-505, 2000
9) Shimada M, Yamashita Y, Aishima S, et al. : Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 88 ; 1463-1466, 2001
10) Tamandl D, Kaczirek K, Gruenberger B, et al. : Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 96 ; 919-925, 2009
11) Okami J, Dono K, Sakon M, et al. : Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. J Gastrointest Surg 7 ; 850-856, 2003
12) 胆道癌診療ガイドライン作成出版委員会編 : 胆道癌診療ガイドライン. 医学図書出版, 2007
P.302 掲載の参考文献
1) Ikai I, Arii S, Okazaki M, et al. : Report of the 17 th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 37 ; 676-691, 2007
2) Khan SA, Thomas HC, Davidson BR, et al. : Cholangiocarcinoma. Lancet 366 ; 1303-1314, 2005
3) 日本肝癌研究会編 : 原発性肝癌取扱い規約 (第5版補訂版), 金原出版, 2009
4) Okusaka T, Ishii H, Funakoshi A, et al. : Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57 ; 647-653, 2006
5) Furuse J, Okusaka T, Boku N, et al. : S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 62 ; 849-855, 2008
6) Yonemoto N, Furuse J, Okusaka T, et al. : A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37 ; 843-851, 2007
7) Valle J, Wasan H, Palmer DH, et al. : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 ; 1273-1281, 2010
8) Okusaka T, Nakachi K, Fukutomi A, et al. : Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer : a comparative multicentre study in Japan. Br J Cancer 103 ; 469-474, 2010
9) Ikeda M, Okusaka T, Mizunuma J, et al. : Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer : Results of the Japan Clinical Oncology Group study (JCOG 0805). JSMO, Abstract # IS1-1, 2012

IV. 肝癌を理解するための基礎研究

P.309 掲載の参考文献
1) Kumar V, Kato N, Urabe Y, et al. : Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 43 ; 455-458, 2011
2) Kohga K, Takehara T, Tatsumi T, et al. : Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 99 ; 1643-1649, 2008
3) Miki D, Ochi H, Hayes CN, et al. : Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 43 ; 797-800, 2011
4) Zhang H, Zhai Y, Hu Z, et al. : Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42 ; 755-758, 2010
5) Sawai H, Nishida N, Mbarek H, et al. : No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet 13 ; 4, 2012
6) Jiang DK, Sun J, Cao G, et al. : Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 45 ; 72-75, 2013
7) Li S, Qian J, Yang Y, et al. : GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 8 ; e1002791, 2012
8) Chan KY, Wong CM, Kwan JS, et al. : Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One 6 ; e28798, 2011
P.313 掲載の参考文献
1) Collins FS, Hamburg MA : First FDA authorization for next-generation sequencer. N Engl J Med 369 ; 2369-2371, 2013
2) Lee W, Jiang Z, Liu J, et al. : The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465 : 473-477, 2010
3) Totoki Y, Tatsuno K, Yamamoto S, et al. : High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43 ; 464-469, 2011
4) Fujimoto A, Totoki Y, Abe T, et al. : Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44 ; 760-764, 2012
5) Kan Z, Zheng H, Liu X, et al. : Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23 ; 1422-1433, 2013
6) Jiang Z, Jhunjhunwala S, Liu J, et al. : The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 22 ; 593-601, 2012
7) Sung WK, Zheng H, Li S, et al. : Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44 ; 765-769, 2012
P.318 掲載の参考文献
1) Yamashita T, Wang XW : Cancer stem cells in the development of liver cancer. J Clin Invest 123 ; 1911-1918, 2013
2) Nault JC, De Reynies A, Villanueva A, et al. : A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenter ology 145 ; 176-187, 2013
3) Hoshida Y, Nijman SM, Kobayashi M, et al. : Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69 ; 7385-7392, 2009
4) Yamashita T, Forgues M, Wang W, et al. : EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 ; 1451-1461, 2008
5) Yamashita T, Budhu A, Forgues M, et al. : Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67 ; 10831-10839, 2007
6) Yamashita T, Ji J, Budhu A, et al. : EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 ; 1012-1024, 2009
7) Yamashita T, Kaneko S : Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. J Gastroenterol 49 ; 1105-1110, 2014
8) Zhao W, Wang L, Han H, et al. : 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha 2 delta 1 subunit. Cancer Cell 23 ; 541-556, 2013
9) Yamashita T, Honda M, Nakamoto Y, et al. : Discrete nature of EpCAM (+) and CD90 (+) cancer stem cells in human hepatocellular carcinoma. Hepatology 57 ; 1484-1497, 2013
10) Zeng SS, Yamashita T, Kondo M, et al. : The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 60 ; 127-134, 2014
P.326 掲載の参考文献
1) 西尾和人, 西條長宏 (編) : がんの分子標的と治療薬辞典. 羊土社, 2010
2) Weinstein IB, Joe A : Oncogene addiction. Cancer Res 68 ; 3077-3080, 2008
3) Dancey JE, Bedard PL, Onetto N, et al. : The genetic basis for cancer treatment decisions. Cell 148 ; 409-420, 2012
4) Kelloff GJ, Sigman CC : Cancer biomarkers : selecting the right drug for the right patient. Nat Rev Drug Discov 11 ; 201-214, 2012
5) McLeod HL : Cancer pharmacogenomics : early promise, but concerted effort needed. Science 339 ; 1563-1566, 2013
6) The cancer genome atlas (http://cancergenome.nih.gov/)
7) Van Allen EM, Wagle N, Levy MA : Clinical analysis and interpretation of cancer genome data. J Clin Oncol 31 ; 1825-1833, 2013
8) Diaz LA Jr, Bardelli A : Liquid biopsies : genotyping circulating tumor DNA. J Clin Oncol 32 ; 579-586, 2014
9) Wilhelm S, Carter C, Lynch M, et al. : Discovery and development of sorafenib : a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 ; 835-844, 2006
10) Woo HY, Heo J : Sorafenib in liver cancer. Expert Opin Pharmacother 13 ; 1059-1067, 2012
11) Shen YC, Lin ZZ, Hsu CH, et al. : Clinical Trials in Hepatocellular Carcinoma : An Update. Liver Cancer 2 ; 345-364, 2013
12) Chan SL, Yeo W : Targeted therapy of hepatocellular carcinoma : present and future. J Gastroenterol Hepatol 27 ; 862-872, 2012
13) Folkman J : Tumor angiogenesis : therapeutic implications. N Engl J Med 285 ; 1182-1186, 1971
14) Yamaguchi R, Yano H, Iemura A, et al. : Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 ; 68-77, 1998
15) Cheng AL, Kang YK, Lin DY, et al. : Sunitinib versus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial. J Clin Oncol 31 ; 4067-4075, 2013
16) Johnson PJ, Qin S, Park JW, et al. : Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma : results from the randomized phase III BRISK-FL study. J Clin Oncol 31 ; 3517-3524, 2013
17) Llovet JM, Decaens T, Raoul JL, et al. : Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed : results from the randomized phase III BRISK-PS study. J Clin Oncol 31 ; 3509-3516, 2013
18) Strumberg D, Schultheis B : Regorafenib for cancer. Expert Opin Investig Drugs 21 ; 879-889, 2012
19) Zhu AX, Rosmorduc O, Evans J, et al. : A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). ESMO 2012
20) Lebwohl D, Anak O, Sahmoud T, et al. : Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 1291 ; 14-32, 2013
21) Santoro A, Rimassa L, Borbath I, et al. : Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study. Lancet Oncol 14 ; 55-63, 2013
22) O'Neil BH, Goff LW, Kauh JS, et al. : Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 29 ; 2350-2356, 2011
P.331 掲載の参考文献
1) Nakamoto Y, Kaneko S : Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 3 ; 537-544, 2003
2) Nakamoto Y, Guidotti LG, Kuhlen CV, et al. : Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998 ; 188 : 341-350.
3) Nakamoto Y, Kaneko S, Fan H, et al. : Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 196 ; 1105-1111, 2002
4) Nakamoto Y, Suda T, Momoi T, et al. : Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 64 ; 3326-3333, 2004
5) Sakai Y, Kaneko S, Nakamoto Y, et al. : Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein- 1 in hepatocellular carcinoma. Cancer Gene Ther 8 ; 695-704, 2001
6) Tsuchiyama T, Kaneko S, Nakamoto Y, et al. : Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 10 ; 260-269, 2003
7) Tsuchiyama T, Nakamoto Y, Sakai Y, et al. : Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol 178 ; 574-583, 2007
8) Marukawa Y, Nakamoto Y, Kakinoki K, et al. : Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma. Cancer Gene Ther 19 ; 312-319, 2012
9) Iida N, Nakamoto Y, Baba T, et al. : Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1 alpha. Cancer Res 70 ; 6556-6565, 2010
10) Nakamoto Y, Mizukoshi E, Tsuji H, et al. : Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma : clinical safety. Clin Exp Immunol 147 ; 296-305, 2007
11) Nakamoto Y, Mizukoshi E, Kitahara M, et al. : Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 163 ; 165-177, 2011

最近チェックした商品履歴

Loading...